Page 10 - Diagnosis, management, and surveillance of neurogenic lower urinary tract dysfunction – Executive Summary

Guideline: Neurogenic bladder

34. Madersbacher H, Murtz G, Stohrer M. Neurogenic detrusor overactivity in adults: A review on efficacy, 51. Wyndaele JJ. Correlation between clinical neurological data and urodynamic function in spinal cord injured
tolerability, and safety of oral antimuscarinics. Spinal Cord 2013;51:432-41. https://doi.org/10.1038/ patients. Spinal Cord 1997;35:213-6. https://doi.org/10.1038/sj.sc.3100391
sc.2013.19 52. Bycroft J, Hamid R, Bywater H, et al. Variation in urological practice amongst spinal injuries units in the
35. Bennett N, O’Leary M, Patel AS, et al. Can higher doses of oxybutynin improve efficacy in neurogenic UK and Eire. Neurourol Urodyn 2004;23:252-6; discussion 7. https://doi.org/10.1002/nau.20005
bladder? J Urol 2004;171:749-51. https://doi.org/10.1097/01.ju.0000103274.38694.b1 53. Gerridzen RG, Thijssen AM, Dehoux E. Risk factors for upper tract deterioration in chronic spinal cord injury
36. Horstmann M, Schaefer T, Aguilar Y, et al. Neurogenic bladder treatment by doubling the recommended patients. J Urol 1992;147:416-8. https://doi.org/10.1016/S0022-5347(17)37254-3
antimuscarinic dosage. Neurourol Urodyn 2006;25:441-5. https://doi.org/10.1002/nau.20289 54. McGuire EJ, Woodside JR, Borden TA, et al. Prognostic value of urodynamic testing in myelodysplastic
37. Amend B, Hennenlotter J, Schäfer T, et al. Effective treatment of neurogenic detrusor dysfunction patients. J Urol 1981;126:205-9. https://doi.org/10.1016/S0022-5347(17)54449-3
by combined high-dosed antimuscarinics without increased side-effects. Eur Urol 2008;53:1021-8. 55. McGuire EJ, Woodside JR, Borden TA, et al. Prognostic value of urodynamic testing in myelodysplas-Prognostic value of urodynamic testing in myelodysplas-
https://doi.org/10.1016/j.eururo.2008.01.007 tic patients, 1981. J Urol 2002;167:1049-53; discussion 54. https://doi.org/10.1016/S0022-
38. Stöhrer M, Blok B, Castro-Diaz D, et al. EAU guidelines on neurogenic lower urinary tract dysfunction. Eur 5347(02)80338-X
Urol 2009;56:81-8. https://doi.org/10.1016/j.eururo.2009.04.028 56. Blok BF, Karsenty G, Corcos J. Urological surveillance and management of patients with neurogenic bladder:
39. Çetinel B, Önal B, Can G, et al. Risk factors predicting upper urinary tract deterioration in patients with Results of a survey among practicing urologists in Canada. Can J Urol 2006;13:3239-43.
spinal cord injury: A retrospective study. Neurourol Urodyn 2017;36:653-8. https://doi.org/10.1002/ 57. Cameron AP, Lai J, Saigal CS, et al; Project NUDiA. Urological surveillance and medical complications
nau.22984 after spinal cord injury in the United States. Urology 2015;86:506-10. https://doi.org/10.1016/j.
40. Kim YH, Bird ET, Priebe M, et al. The role of oxybutynin in spinal cord injured patients with indwelling urology.2015.06.005
catheters. J Urol 1997;158:2083-6. https://doi.org/10.1016/S0022-5347(01)68161-8 58. Razdan S, Leboeuf L, Meinbach DS, et al. Current practice patterns in the urologic surveillance and
41. Wollner J, Pannek J. Initial experience with the treatment of neurogenic detrusor overactivity with a management of patients with spinal cord injury. Urology 2003;61:893-6. https://doi.org/10.1016/
new [beta]-3 agonist (mirabegron) in patients with spinal cord injury. Spinal Cord 2016;54:78-82. S0090-4295(02)02518-9
https://doi.org/10.1038/sc.2015.195 59. Welk B, Liu K, Shariff SZ. The use of urologic investigations among patients with traumatic spinal cord
42. Welk B. Urodynamic and clinical efficacy of mirabegron for neurogenic bladder patients. Ongoing study: injuries. Res Rep Urol 2016;8:27-34. https://doi.org/10.2147/RRU.S99840
Clinical Trials.Gov Identifier NCT02044510. 60. Soergel TM, Cain MP, Misseri R, et al. Transitional cell carcinoma of the bladder following augmenta-Transitional cell carcinoma of the bladder following augmenta-
43. Schurch B, de Seze M, Denys P, et al. Botulinum toxin type A is a safe and effective treatment for tion cystoplasty for the neuropathic bladder. J Urol 2004;172:1649-51; discussion 51-2. https://doi.
neurogenic urinary incontinence: Results of a single treatment, randomized, placebo controlled 6-month org/10.1097/01.ju.0000140194.87974.56
study. J Urol 2005;174:196-200. https://doi.org/10.1097/01.ju.0000162035.73977.1c 61. Higuchi TT, Granberg CF, Fox JA, et al. Augmentation cystoplasty and risk of neoplasia: Fact, fiction, and
44. Cruz F, Herschorn S, Aliotta P, et al. Efficacy and safety of onabotulinumtoxinA in patients with urinary controversy. J Urol 2010;184:2492-6. https://doi.org/10.1016/j.juro.2010.08.038
incontinence due to neurogenic detrusor overactivity: A randomized, double-blind, placebo-controlled trial. 62. Higuchi TT, Fox JA, Husmann DA. Annual endoscopy and urine cytology for the surveillance of blad -
Eur Urol 2011;60:742-50. https://doi.org/10.1016/j.eururo.2011.07.002 der tumours after enterocystoplasty for congenital bladder anomalies. J Urol 2011;186:1791-5.
45. Mehta S, Hill D, McIntyre A, et al. Meta-analysis of botulinum toxin A detrusor injections in the treatment https://doi.org/10.1016/j.juro.2011.07.028
of neurogenic detrusor overactivity after spinal cord injury. Arch Phys Med Rehabil 2013;94:1473-81. 63. Hamid R, Greenwell TJ, Nethercliffe JM, et al. Routine surveillance cystoscopy for patients with augmenta-
https://doi.org/10.1016/j.apmr.2013.04.011 tion and substitution cystoplasty for benign urological conditions: Is it necessary? BJU Int 2009;104:392-5.
46. Mangera A, Apostolidis A, Andersson KE, et al. An updated systematic review and statistical comparison https://doi.org/10.1111/j.1464-410X.2009.08401.x
of standardized mean outcomes for the use of botulinum toxin in the management of lower urinary tract 64. Linsenmeyer TA, Linsenmeyer MA. Impact of annual urodynamic evaluations on guiding bladder manage-Impact of annual urodynamic evaluations on guiding bladder manage-
disorders. Eur Urol 2014;65:981-90. https://doi.org/10.1016/j.eururo.2013.10.033 ment in individuals with spinal cord injuries. J Spinal Cord Med 2013;36:420-6. https://doi.org/10.1
47. Cheng T, Shuang WB, Jia DD, et al. Efficacy and safety of onabotulinumtoxinA in patients with neurogenic 179/2045772313Y.0000000106
detrusor overactivity: A systematic review and meta-analysis of randomized controlled trials. PLoS One 65. Nosseir M, Hinkel A, Pannek J. Clinical usefulness of urodynamic assessment for maintenance
2016;11:e0159307. https://doi.org/10.1371/journal.pone.0159307 of bladder function in patients with spinal cord injury. Neurourol Urodyn 2007;26:228-33.
48. Ginsberg D, Gousse A, Keppenne V, et al. Phase 3 effi cacy and tolerability study of onabotulinum-Phase 3 efficacy and tolerability study of onabotulinum- https://doi.org/10.1002/nau.20319
toxinA for urinary incontinence from neurogenic detrusor overactivity. J Urol 2012;187:2131-9. 66. Edokpolo LU, Foster HE Jr. Renal tract ultrasonography for routine surveillance in spinal cord injury patients.
https://doi.org/10.1016/j.juro.2012.01.125 Top Spinal Cord Inj Rehabil 2013;19:54-60. https://doi.org/10.1310/sci1901-54
49. Food and Drug Administration. Highlights of prescribing information Botox 2016. Available at: www.
®
accessdata.fda.gov/drugsatfda_docs/label/2016/103000s5252lbl.pdf. Accessed May 2, 2019. Correspondence: Dr. Alex Kavanagh, Department of Urologic Sciences, University of British Columbia,
50. Del Popolo G, Filocamo MT, Li Marzi V, et al. Neurogenic detrusor overactivity treated with Vancouver, BC, Canada; alexgkava@gmail.com
english botulinumtoxinA: 8-year experience of one single centre. Eur Urol 2008;53:1013-9.
https://doi.org/10.1016/j.eururo.2007.09.034

CUAJ • June 2019 • Volume 13, Issue 6 165